Categories
Change Password!
Reset Password!
Sphingosine 1-phosphate receptor modulators are effective and safe for treating moderate-to-severe ulcerative colitis.
In a recent study published in the "Journal of Clinical Gastroenterology", the use of Sphingosine 1-phosphate receptor modulators (S1PRMs) proved beneficial for patients with moderate-to-severe ulcerative colitis (UC).
This systematic review and meta-analysis scrutinized the efficacy and safety of S1PRMs by examining pooled data from various randomized controlled trials (RCTs) involving adults with moderate to severe UC, identified through a comprehensive search of multiple databases.
Investigators performed a meta-analysis using a random effects model, evaluated the risk of bias with the Cochrane Risk-of-Bias 2 tool, and rated evidence quality with the GRADE approach. The analysis included 7 trials with 1,737 patients.
S1PRM therapy showed prominent benefits over placebo during induction for various outcomes, including clinical remission (risk ratio [RR]: 2.65), clinical response (RR: 1.68), endoscopic improvement (RR: 2.17), endoscopic normalization (RR: 2.56), mucosal healing (RR: 2.88), and histologic remission (RR: 2.42). Maintenance therapy with S1PRMs also demonstrated enhanced efficacy for sustained (RR: 3.57) and steroid-free remission (RR: 2.92). Importantly, there were no vital differences in adverse events (RR: 1.02) or infections (RR: 1.15) when comparing S1PRM to placebo. Thus, S1PRM therapy appears to be an effective and safe choice for UC management.
Journal of Clinical Gastroenterology
Efficacy and Safety of Sphingosine 1-Phosphate Receptor Modulators for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mahmud Omar et al.
Comments (0)